Connect your agent to akta.pro and build company lists like this across sectors and geos.
This dashboard ranks the 10 most recent qualifying biotechnology companies in the United States with new CEO hires during the stated window, using complete LG01 coverage and company-HQ verification. Rows add industry, firmographics, estimated revenue, funding, mandate and article sources.
| # | Date | Company | Industry / category | Firmographics | Est. revenue | Funding | Executive appointment | Mandate | Sources |
|---|---|---|---|---|---|---|---|---|---|
| 01 | Sep 15, 2026 | Legend Biotech↗ Public | Oncology Cell Therapies Healthcare & Life Sciences Biotechnology & Biologics | Piscataway, US Founded 2014 · 1001-5000 emp. | — | — | Ingrid Zhang Previously Chief Commercial Officer · Novartis Chief Executive Officer | Strategy & Transformation Leads Legend Biotech as CEO succeeding interim CEO Alan Bash, who resumes as President of CARVYKTI, following Ying Huang's abrupt departure. | StockTitanStockTitan 2 sources |
| 02 | Sep 14, 2026 | Shennon Biotechnologies↗ Private · Venture Growth Investor Backed | Immunotherapy Drug Discovery Platform Healthcare & Life Sciences Biotechnology & Biologics | San Francisco, US Founded 2021 · 11-50 emp. | Pre-revenue | $25M | Cyril Konto, M.D. Chief Executive Officer | Product & Technology Appointed alongside a $12M financing to move three T-cell engager programs toward IND filing; founder Li Sun becomes president and CTO. | Business Wire 1 source |
| 03 | Sep 11, 2026 | Callio Therapeutics↗ Private · Venture Growth Investor Backed | Oncology Biopharmaceuticals (ADC Therapeutics) Healthcare & Life Sciences Biotechnology & Biologics | Seattle, US Founded 2025 · 1-10 emp. | — | — | Zachary Hornby Chief Executive Officer | Strategy & Transformation Leads Callio Therapeutics to advance its dual-payload ADC pipeline, including lead candidate CLIO-8221 in Phase 1/2 trials for HER2-expressing tumors. | Pulse2 1 source |
| 04 | Sep 1, 2026 | Invivyd↗ Public | Biopharmaceutical Antibody Development Healthcare & Life Sciences Biotechnology & Biologics | Waltham, US Founded 2020 · 101-250 emp. | — | — | Marc Elia Chief Executive Officer & Chairman | Strategy & Transformation Appointed CEO and Chairman as Invivyd nears completion of Phase 3 trials for VYD2311, a COVID-19 monoclonal antibody. | QuiverQuant 1 source |
| 05 | Sep 1, 2026 | Immunophotonics↗ Private · Venture Growth Investor Backed | Cancer Immunotherapy Healthcare & Life Sciences Biotechnology & Biologics | St Louis, US Founded 2011 · 11-50 emp. | Pre-revenue | $42M | Robert H. Arch, Ph.D. President and Chief Executive Officer | Product & Technology Named CEO with an initial $10M Series C to advance IP-001 clinical development and Phase 2 programs in interventional immuno-oncology. | EIN Presswire 1 source |
| 06 | Aug 19, 2026 | BioSkryb Genomics↗ Private · Venture Growth Investor Backed | Single Cell Genomics Platform Healthcare & Life Sciences Life Science Tools & Services | Durham, US Founded 2018 · 11-50 emp. | — | — | William E. Evans Previously CEO · St. Jude Children's Research Hospital Chief Executive Officer | Strategy & Transformation Succeeds Suresh Pisharody to advance BioSkryb Genomics single-cell genomics platform into clinical applications. | citybiz 1 source |
| 07 | Aug 18, 2026 | Longevica↗ Private · Venture Growth Investor Backed | Longevity Pharmaceuticals And Supplements Healthcare & Life Sciences Biotechnology & Biologics | Princeton, US Founded 2009 · 1-10 emp. | — | — | Dr. Prasun Mishra Chief Executive Officer | Strategy & Transformation Leads Longevica Therapeutics transition from discovery research to preclinical drug development for longevity therapies. | citybiz 1 source |
| 08 | Aug 17, 2026 | Juvena Therapeutics↗ Private · Venture Growth Investor Backed | Regenerative Biopharmaceuticals Healthcare & Life Sciences Biotechnology & Biologics | Palo Alto, US Founded 2017 · 11-50 emp. | Pre-revenue | $113.2M | Julie Anne Smith Chief Executive Officer | Product & Technology Takes over as JUV-161 enrolls a Phase 2a trial in myotonic dystrophy and the platform advances through a collaboration with Eli Lilly. | 01netFierceBiotech 2 sources |
| 09 | Jul 27, 2026 | Sarepta Therapeutics↗ Public | Gene And Rna Therapies Healthcare & Life Sciences Biotechnology & Biologics | Cambridge, US Founded 1987 · 501-1000 emp. | — | — | Michael Severino, M.D. Previously CEO · Tessera Therapeutics Chief Executive Officer | Strategy & Transformation Replaces Doug Ingram; Severino previously served as Vice Chairman and President at AbbVie and CEO of Flagship Pioneering's Tessera Therapeutics. | StockTitanFierce Pharma 2 sources |
| 10 | Jul 23, 2026 | Tessera Therapeutics↗ Private · Venture Growth Investor Backed | Genome Editing Therapeutics Healthcare & Life Sciences Biotechnology & Biologics | Cambridge, US Founded 2018 · 251-500 emp. | — | — | Joseph Romanelli Previously Merck & Co. President & Chief Executive Officer | Strategy & Transformation Succeeds Michael Severino, who departed to become CEO of Sarepta Therapeutics; Romanelli is a veteran pharmaceutical executive from Merck. | StockTitan 1 source |
This page treats a leadership hire as a source-grounded appointment, promotion, or explicit expansion into a senior operating role at an eligible company. The event must identify the executive and new title, fall inside the stated date window, and satisfy the requested leadership scope. For new CEO, a keyword appearing only in the company name or surrounding article is not enough; the title or reported mandate must actually match the requested function.
Geography is assigned from the company's akta.pro record, not from a publisher location, article dateline, executive location, or News Signals country tag. That distinction matters because syndicated coverage of one appointment can carry different country labels. When an industry filter is requested, the company must also match the approved akta.pro industry taxonomy used for ListGen or Company Data. Revenue and funding are descriptive enrichment fields and never determine whether a company qualifies or how it ranks.
The ranking is company-level rather than article-level. Multiple articles about the same appointment are merged into one LG01 event, and multiple qualifying appointments at the same company are counted but collapsed to the newest event for the displayed row. Companies are ordered by appointment announcement date, then by the number of distinct supporting sources, then alphabetically. The initial ListGen coverage set is twice the requested list size, while the broad LG01 pull protects against missing a recent hire simply because the company was absent from that coverage sample. If fewer than the requested number qualify, the page shows the smaller verified set instead of weakening the evidence standard.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICSIndustry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.